Aarti Drugs Ltd. - Research Center
524348 AARTIDRUGS Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 1,176.03 | 1,234.69 | 1,016.48 | 990.71 | 822.18 |
| Operating profit | 124.91 | 174.78 | 143.40 | 225.07 | 126.90 |
| Interest | 15.06 | 10.84 | 9.22 | 13.37 | 15.32 |
| Gross profit | 110.18 | 166.18 | 136.71 | 213.20 | 112.32 |
| EPS (Rs) | 6.80 | 11.75 | 9.30 | 61.29 | 35.76 |
Half yearly
results in details
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 0.33 | 2.24 | 2.53 | 1.50 | 0.74 |
| Stock adjustment | -75.06 | -25.77 | -52.17 | -6.66 | -21.99 |
| Raw material | 865.59 | 824.67 | 700.12 | 581.14 | 531.55 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 34.74 | 35.67 | 33.65 | 35.24 | 30.98 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 225.85 | 225.34 | 191.48 | 155.92 | 154.74 |
| Provisions made | - | - | - | - | - |
| Depreciation | 23.75 | 23.83 | 23.56 | 23.89 | 23.84 |
| Taxation | 23.50 | 33.50 | 27.00 | 46.50 | 13.55 |
| Net profit / loss | 62.93 | 108.85 | 86.15 | 142.81 | 83.31 |
| Extra ordinary item | - | - | - | - | 8.38 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 92.60 | 92.60 | 92.60 | 23.30 | 23.30 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 10.62 | 14.16 | 14.11 | 22.72 | 15.43 |
| GPM (%) | 9.37 | 13.43 | 13.42 | 21.49 | 13.65 |
| NPM (%) | 5.35 | 8.80 | 8.45 | 14.39 | 10.12 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis